709 filings
Page 4 of 36
8-K
287bbevg8 i56g
12 Nov 21
Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:29am
8-K
kq9unush045hp5em6
28 Oct 21
Issuance further expands and strengthens Company’s intellectual property portfolio
8:29am
8-K
1nt0m2ss
23 Sep 21
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia
8:29am
8-K
3epmuk4jsy
7 Sep 21
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
8:29am
8-K
qzpax7ksjur 9h4nsd
12 Aug 21
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
kicgnc0hqt
3 Aug 21
Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent
8:29am
UPLOAD
ka51qbj
12 Jul 21
Letter from SEC
12:00am
8-K
nlseh7qsvdge
7 Jul 21
Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure
8:29am
8-K
jv7fgg9h97ejknfndiw
6 Jul 21
Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference
8:29am
S-8
3kcfyfs6ulk7 j4hf
2 Jul 21
Registration of securities for employees
4:19pm
8-K
yfpstmn
25 Jun 21
Departure of Directors or Certain Officers
4:02pm
DEFA14A
p253gvanhplqfqer
16 Jun 21
Additional proxy soliciting materials
7:03am
8-K
dq539i0 xrph
16 Jun 21
Amendments to Articles of Incorporation or Bylaws
7:01am
8-K
ht2b8yw4vlzizihw cz
10 Jun 21
Issuance expands patent claims for Company’s dual-energy technology
8:29am
8-K
ocsvs9dgu3u92qkn4zug
2 Jun 21
Viveve Announces Adjournment of Annual Meeting
4:10pm
DEFA14A
o8yxe8kuzwrb
2 Jun 21
Additional proxy soliciting materials
4:08pm